IP Library Patent Application 13317666
Patent Application
App. No. 13/317,666

Tuberculosis treatment using pleuromutilin derivatives

Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US None
App. No.
13/317,666
Abstract

A method of preventing or treating diseases caused by Mycobacterium , comprising administering to a subject in need of such treatment an effective amount of a pleuromutilin.

Claims (33)

1 . A compound selected from the group consisting of compounds of formulae as set out in TABLE 1:

TABLE 1

2 . A compound of formula

wherein

the dotted line is a bond (double bond between positions a=b), R 1A is hydrogen and R 2A is not present, or

the dotted line is no bond (single bond between positions a-b) and R 1A and R 2A independently of each other are hydrogen, halogen or deuterium,

R 3A is (C 1-6 )alkyl,

R 4A is hydrogen, (C 1-6 )alkyl, a group —C(═NH)—NH 2 , or the residue of an amino acid,

R 5A is hydrogen, or

R 4A and R 5A together are a group ═CH—NH 2 ,

R 6A is hydrogen or deuterium, and

m A is 0, 1, 2, 3, 4, or 5.

3 . A compound of formula

wherein

R 1C has the meaning of R 1A as defined in claim 2 ,

R 2C has the meaning of R 2A as defined in claim 2 ,

the dotted line has the meaning as defined in claim 2 ,

R 4C has the meaning of R 6A as defined in claim 2 , and

R 3C is amino, (C 1-4 )alkylamino, di(C 1-4 )alkylamino, the residue of an amino acid, hydroxy, or (C 1-4 )alkoxy.

4 . A compound of formula

wherein

R 1D has the meaning of R 1A as defined in claim 2 ,

R 2D has the meaning of R 2A as defined in claim 2 ,

R 4D has the meaning of R 6A as defined in claim 2 ,

the dotted line has the meaning as defined in claim 2 , and

R 3D is aliphatic heterocyclyl of 4 to 8 ring members, and comprising one nitrogen atom as the heteroatom, or (C 4-8 )cycloalkyl, which heterocyclyl or cycloalkyl is substituted by hydroxy or oxo.

5 . The compound of claim 2 in the form of a salt.

6 . The compound of claim 2 for use as a pharmaceutical.

7 . A pharmaceutical composition comprising a compound of claim 2 in association with at least one pharmaceutical excipient.

8 . The pharmaceutical composition according to claim 6 , further comprising another pharmaceutically active agent.

9 . A pharmaceutical composition comprising a pleuromutilin in association with at least one pharmaceutical excipient, and further comprising another pharmaceutically active agent useful in the treatment of Mycobacterium infections.

10 . The compound of claim 2 for use in the preparation of a medicament for the treatment of microbial diseases.

11 . A method of treatment of microbial diseases, wherein said method comprises administering to a subject in need of such treatment an effective amount of a compound of claim 2 .

Assignments (3)
RELEASE OF SECURITY INTEREST Recorded Jan 11, 2016
From: KREOS CAPITAL IV (UK) LIMITED
To: NABRIVA THERAPEUTICS AG
Reel/Frame 037455/0436 →
SECURITY INTEREST Recorded Aug 28, 2014
From: NABRIVA THERAPEUTICS AG
To: KREOS CAPITAL IV (UK) LIMITED
Reel/Frame 033647/0657 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jun 28, 2012
From: ASCHER, GERD; STAUFFER, FRIEDRICH; BERNER, HEINZ; RIEDL, ROSEMARIE
To: NABRIVA THERAPEUTICS AG
Reel/Frame 028461/0245 →